Trials / Completed
CompletedNCT00781976
Antiviral Activity of AZD7295 in HCV Carriers
A Randomised, DB, PC Study to Determine the PK, Safety and Tolerability Profile and Antiviral Activity of Multiple Oral Doses of AZD7295 in Otherwise Healthy Male and Female Hepatitis C Carriers With Compensated Liver Disease
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 31 (actual)
- Sponsor
- Arrow Therapeutics · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
PK, safety study of AZD7295 in HCV carriers
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AZD7295 | 700mg per day maximum |
| DRUG | Placebo | matched placebo |
Timeline
- Start date
- 2008-11-01
- Primary completion
- 2010-03-01
- Completion
- 2010-03-01
- First posted
- 2008-10-29
- Last updated
- 2010-03-31
Locations
1 site across 1 country: New Zealand
Source: ClinicalTrials.gov record NCT00781976. Inclusion in this directory is not an endorsement.